Law360, New York (October 16, 2009) -- The Alabama Supreme Court has overturned two jury decisions awarding the state nearly $275 million from three pharmaceutical companies, which the state accused of ripping off its Medicaid program by fraudulently inflating the price of their prescription drugs.
In an 8-1 opinion the court ruled in favor of appellants AstraZeneca LP, Novartis Pharmaceuticals Corp and GlaxoSmithKline, finding that as a matter of law the state cannot claim that...
